Reed Tuckson
HENRY SCHEINAbout Reed V. Tuckson
Reed V. Tuckson, M.D., FACP (age 74) is an independent director of Henry Schein, Inc. since 2021. He is Managing Director of Tuckson Health Connections, co-founder/convener of the Black Coalition Against COVID-19, and co-founder/Board Chair of the Coalition For Trust in Health & Science; prior roles include EVP and Chief of Medical Affairs at UnitedHealth Group and significant public-sector health leadership. Education: M.D. (Georgetown University), B.S. (Howard University), and completed General Internal Medicine residency/fellowship at University of Pennsylvania Hospital as a Robert Wood Johnson Foundation Clinical Scholar at Wharton .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| UnitedHealth Group | EVP & Chief of Medical Affairs | 2006–2013 | Senior medical leadership across payer operations |
| District of Columbia | Commissioner of Public Health | Not disclosed | Public sector health leadership |
| American Medical Association | SVP, Professional Standards | Not disclosed | Standards and physician policy leadership |
| March of Dimes Birth Defects Foundation | SVP | Not disclosed | Maternal/child health advocacy |
| Charles R. Drew University of Medicine & Science | President | Not disclosed | Academic health leadership |
| National Academy of Medicine | Various appointed roles | Not disclosed | National health policy leadership |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Adverum Biotechnologies, Inc. | Director | 2021–Present | Private company board |
| CTI BioPharma Corp | Director; Nominating & Governance Chair; Audit member | 2011–2023 | Public company (tenure ended 2023) |
| Acasti Pharma, Inc. | Director | 2013–2016 | Public company |
| LifePoint Health, Inc. | Director | 2014–2018 | Public company (provider) |
| Baxter International, Inc. | Director | 1996–1998 | Public company (medical products) |
| Johns Hopkins Berman Institute of Bioethics | Advisory Board Member | Not disclosed | Non-profit |
| Freedom House | Trustee | Not disclosed | Non-profit |
| The Hastings Center | Board Member | Not disclosed | Non-profit |
Board Governance
- Committee Membership: Strategic Advisory Committee (member) .
- Independence: Affirmed independent under Nasdaq Rule 5605(a)(2) .
- Attendance: All directors attended at least 75% of Board/committee meetings in FY2024; SAC met 3 times in FY2024 .
- Annual Meeting Attendance: All directors then in office except Mohamad Ali and James P. Breslawski attended the 2024 Annual Meeting (implies Dr. Tuckson attended) .
- Executive Sessions: Independent directors meet in regular executive sessions without management .
Fixed Compensation
| Component | FY2024 Amount/Rate | Notes |
|---|---|---|
| Fees Earned or Paid in Cash | $106,600 | Total cash fees for Dr. Tuckson in FY2024 |
| Annual Board Retainer | $100,000 | Increased from $90,000 in Feb 2024 |
| Committee Meeting Fee | $2,200 per meeting | Applies to each committee meeting attended |
| Chair Retainers | N/A for Tuckson | Chair retainers range $15,000–$25,000 depending on committee; Lead Director $40,000 |
Performance Compensation
- Non-Employee Directors do not receive options or performance-based annual bonuses .
- RSU Awards:
- FY2024 grant: 2,604 RSUs; grant date March 4, 2024; grant-date fair value $200,000; 12-month time-based cliff vest; full accelerated vesting upon change-in-control; deferral elections permitted (3/5/7/10 years or termination) .
- Plan annual limit: Cash + equity for any non-employee director capped at $900,000 per fiscal year .
| RSU Detail | FY2024 Grant | Vesting | Change-in-Control | Deferral Elected (as of FY2024 YE) |
|---|---|---|---|---|
| RSUs (#) | 2,604 | 12-month cliff (time-based) | Full accelerated vesting (no termination prior to CIC) | 2,217 vested RSUs with deferred payment outstanding |
Other Directorships & Interlocks
- No current disclosed interlocks with Henry Schein competitors, suppliers, or customers; prior public board roles include Baxter (1996–1998), LifePoint (2014–2018), CTI BioPharma (2011–2023), Acasti (2013–2016) .
Expertise & Qualifications
- Healthcare industry expertise across payer, provider, academia, and policy; recognized leader over 35 years .
- Public sector/government experience via numerous federal advisory committees and D.C. Public Health Commissioner .
- Public company governance experience on multiple healthcare boards .
- Education: M.D. Georgetown; B.S. Howard; UPenn residency/fellowship; RWJ Clinical Scholar at Wharton .
Equity Ownership
| Metric | Amount | Notes |
|---|---|---|
| Shares Beneficially Owned | 7,586 | 5,369 directly owned + 2,217 vested RSUs with deferred payment |
| Percent of Class | * | Less than 0.50% of common stock |
| Unvested RSUs Outstanding (at FY2024 YE) | 2,604 | From March 4, 2024 grant |
| Anti-Hedging / Anti-Pledging | Prohibited | Company policy prohibits hedging and pledging by directors |
| Stock Ownership Guideline | ≥10,000 shares or ≥5x annual retainer | Compliance window 5 years for new directors; all non-employee directors are in compliance |
Governance Assessment
- Strengths: Independent, active committee member (Strategic Advisory), good attendance, and equity alignment via RSUs with optional deferral; anti-hedging/pledging policies and formal ownership guidelines support investor alignment .
- Director pay mix: Cash retainer plus modest meeting fees; equity delivered as time-based RSUs, no options or bonus (reduces risk-taking incentives and aligns with steady governance roles) .
- Potential conflicts: None disclosed involving Dr. Tuckson; Audit Committee oversees related-party transactions and reviewed KKR strategic partnership; familial transactions disclosed relate to other executives, not Dr. Tuckson .
- RED FLAGS: None evident for pledging/hedging, related-party transactions, or attendance; no director options or incentive bonus that could misalign oversight judgment .
Signals for investors: Tuckson’s deep healthcare and public-policy expertise, combined with independence and active engagement on the Strategic Advisory Committee, supports board effectiveness. The director compensation structure and compliance with ownership guidelines indicate alignment without excessive risk incentives .